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Background: The established methods for detecting prostate cancer (CaP) are based on tests using PSA (blood),
PCA3 (urine), and AMACR (tissue) as biomarkers in patient samples. The demonstration of ERG oncoprotein
overexpression due to gene fusion in CaP has thus provided ERG as an additional biomarker. Based on this, we
hypothesized that ERG protein quantification methods can be of use in the diagnosis of prostate cancer.
Methods: An antibody-free assay for ERG3 protein detection was developed based on PRISM (high-pressure
high-resolution separations with intelligent selection and multiplexing)-SRM (selected reaction monitoring) mass
spectrometry. We utilized TMPRSS2-ERG positive VCaP and TMPRSS2-ERG negative LNCaP cells to simulate three different
sample types (cells, tissue, and post-DRE urine sediment). Enzyme-linked immunosorbent assay (ELISA), western blot,
NanoString, and qRT-PCR were also used in the analysis of these samples.
Results: Recombinant ERG3 protein spiked into LNCaP cell lysates could be detected at levels as low as 20 pg by
PRISM-SRM analysis. The sensitivity of the PRISM-SRM assay was approximately 10,000 VCaP cells in a mixed cell
population model of VCaP and LNCaP cells. Interestingly, ERG protein could be detected in as few as 600 VCaP cells
spiked into female urine. The sensitivity of the in-house ELISA was similar to the PRISM-SRM assay, with detection of
30 pg of purified recombinant ERG3 protein and 10,000 VCaP cells. On the other hand, qRT-PCR exhibited a higher
sensitivity, as TMPRSS2-ERG transcripts were detected in as few as 100 VCaP cells, in comparison to NanoString
methodologies which detected ERG from 10,000 cells.
Conclusions: Based on this data, we propose that the detection of both ERG transcriptional products with RNA-based
assays, as well as protein products of ERG using PRISM-SRM assays, may be of clinical value in developing diagnostic
and prognostic assays for prostate cancer given their sensitivity, specificity, and reproducibility.
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Human cancers are commonly stratified by expression sta-
tus and/or mutation of cancer causing genes and their
encoded proteins. Genetic rearrangements involving DNA
sequences from different chromosomes or intrachromoso-
mal regions have been extensively documented in various
cancers, including prostate cancer (CaP) [1]. It has been
reported that several ETS transcription factors play im-
portant roles in CaP as a result of genetic rearrangements.
Of these, overexpression of the ETS-related gene (ERG)
[2,3], resulting from the fusion of ERG coding sequences
to the androgen-responsive TMPRSS2 gene [4], represents
the most common subtype, with a prevalence of approxi-
mately 50% in clinically localized prostate cancers [1,5-11].
In addition, studies evaluating the expression of ERG in
matched benign and malignant prostate tissues from a
large patient cohort indicated that CaP cells harboring
TMPRSS2-ERG fusions showed overexpression of ERG
in 60-70% of patients [8]. This genomic rearrangement
is now established as one of the most common mecha-
nisms of oncogenic activation in CaP [6,9,12]. ERG
overexpression has also been implicated in a diverse
number of cancers, including Ewing’s sarcoma and
acute myeloid leukemia [13-15].
A major goal in CaP is to define protein and antibody
markers which may facilitate early detection, distinguish
indolent from aggressive disease, define treatment strat-
egies, and allow follow up of patients. The prevalence of
ERG overexpression has therefore provided an impetus for
the development of detection assays for TMPRSS2-ERG
mRNA in cells from tissues or urine samples from CaP
patients [16,17]. Currently, real-time quantitative reverse
transcription PCR (qRT-PCR), which detects the presence
of TMPRSS2-ERG fusion transcripts, is routinely used in
research and clinical laboratories. However, the selection
of primer-probe sets used for evaluation has resulted in
variable sensitivity in the detection of the respective RNA.
This has led to the development of monoclonal and poly-
clonal antibodies for the detection of ERG protein for
diagnostic and/or therapeutic purposes [18-20]. In this re-
gard, a mouse monoclonal antibody (MAb) against ERG
was developed in our laboratory. One of the ERG MAb
clones, 9FY, recognized an epitope formed by the amino
acid sequence GQTSKMSPRVPQQDWLSQPPARVTI,
which corresponds to residue positions 42-66 in the ERG
protein [NCBI Reference Sequence: NP_891548.1] [18,21].
The 9FY monoclonal antibody was found to be highly spe-
cific in the detection of ERG protein in cell culture-based
experiments and human prostate cancer specimens by
immunofluorescence and immunohistochemistry (IHC),
respectively, without cross-reactivity to other members
of the ETS family [18,20]. Similar observations were also
reported for a rabbit monoclonal antibody using the
C-terminal peptide of ERG as an immunogen [19,22].Recent analysis of whole mount prostate sections
from age and pathologic stage matched specimens
from over 180 patients revealed that there is a striking
difference in ERG expression in African American and
Caucasian American patients [20]. Much lower fre-
quencies (10-27%) of ERG alterations have been re-
ported in studies from China, Japan, and India [23-26].
This overexpression of ERG protein in prostate cancer
cells may result in a scenario in which the protein may
also be released in body fluids, either through a non-
classical secretory pathway and/or lysis of cells, provid-
ing ERG as a marker associated with the distinct stage
of the disease.
While IHC is ideal for the analysis of biopsied tissues
from patients, assays to quantitate ERG protein are desir-
able for the analysis of cells in blood and urine samples.
As there are no commercially available serologic assays for
ERG, there is a need to develop assays that are sensitive,
accurate, and offer the flexibility of testing multiple target
proteins simultaneously. Emerging targeted proteomic
technologies, exemplified by the selected reaction moni-
toring mass spectrometry (SRM-MS), are ideal for
achieving these goals with high multiplexing capability
and good reproducibility [27-29]. However, a major
limitation of SRM-based targeted quantification is
the lack of sufficient sensitivity for measuring low
abundance proteins. To address this issue, we recently
developed an antibody-independent strategy, termed
high-pressure high-resolution separations with intelligent
selection and multiplexing (PRISM), for significantly enhan-
cing the SRM sensitivity by at least 100-fold when com-
pared to conventional liquid chromatography (LC)-SRM
[30-32]. More recently, PRISM-SRM assays have been
utilized for accurately measuring 16 distinct peptides
from various domains of TMPRSS2-ERG gene fusion
products in prostate cancer cell lines and patient-derived
tumor tissues [33].
In the present study we have systematically evaluated
the performance of multiple platforms for the sensitive
quantification of ERG expression at the protein and
mRNA levels: PRISM-SRM, enzyme-linked immunosorb-
ent assay (ELISA), and western blot assays for ERG pro-
tein; qRT-PCR and NanoString assays for TMPRSS2-ERG
mRNA. In our knowledge, this is the first time a compara-
tive, unbiased evaluation of different platforms analyzing a
similar source of samples has been performed for the as-
sessment of ERG. We utilized TMPRSS2-ERG positive
VCaP and TMPRSS2-ERG negative LNCaP cells to simu-
late three different sample types (cells, tissue, and post-
DRE urine sediment) for these protein and mRNA
measurements. Our results demonstrate that different
analytical platforms vary in their ability to quantify ERG
protein or mRNA, and provide a basis for ERG testing in
patient samples for diagnostic and prognostic purposes.
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Cell culture
Vertebral-Cancer of the Prostate (VCaP) cells, Lymph
Node Carcinoma of the Prostate (LNCaP), and human
embryonic kidney 293 (HEK293) cells were obtained from
American Type Culture Collection (ATCC, Manassas,
VA). VCaP and HEK293 cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM; ATCC) supplemented
with 10% fetal bovine serum (FBS; ATCC). LNCaP cells
were cultured in Roswell Park Memorial Institute-1640
medium (RPMI-1640; Life Technologies, Carlsbad, CA)
supplemented with 10% FBS. All cells were cultured in hu-
midified conditions, at 37°C with 5% CO2.
Sample preparation
Recombinant full length ERG protein, produced in
mammalian cells by exogenous expression, was pur-
chased from Origene (Rockville, MD). HEK293, LNCaP,
and VCaP cells were harvested by trypsinization, diluted
in PBS, and counted by using a hemocytometer. HEK293
and LNCaP cells were aliquoted at 1,000,000 cells/ml
into Eppendorf tubes and pelleted with or without the
addition of VCaP cells. Three sample types were pre-
pared: 1) Purified recombinant ERG was incrementally
spiked into 1,000,000 LNCaP or HEK293 cell lysates
which are negative for TMPRSS2-ERG; 2) TMPRSS2-ERG
fusion positive VCaP cells were titrated into 1,000,000
LNCaP cells incrementally, and pelleted by centrifugation;
3) VCaP cells were incrementally spiked into 5 mL urine
donated by female volunteers, collected as per an ap-
proved IRB protocol. All samples were prepared at CPDR,
and used by both PNNL and CPDR for analyses of ERG.
PRISM-SRM protein extraction and digestion
Proteins were extracted from sample types 1 and 2 (see
above) directly, using a urea solution (8 M urea in 50 mM
NH4HCO3); sample type 3 was first centrifuged at 4,000 ×
g for 45 min in an Amicon Ultra-4 concentrator with
10 kDa molecular weight cutoff (EMD Millipore, Billerica,
MA), followed by protein extraction from the concen-
trated sample using the same urea solution. Cells were
sonicated for 1 min, chilled on ice for 1 min, which was
repeated for a total of three times, and the protein con-
centration was determined using the bicinchoninic acid
(BCA) assay (Pierce, Rockford, IL). Proteins in each
sample were reduced with 10 mM dithiothreitol at 37°C
for 1 h and alkylated using 40 mM iodoacetamide at
room temperature for 1 h in the dark. Samples were
then diluted 10-fold with 50 mM NH4HCO3 and 1 M
CaCl2 was added to each sample to reach a final con-
centration of 1 mM. Protein digestion was performed at
37°C for 3 h using trypsin (Affymetrix, Santa Clara, CA)
at a 1:50 enzyme-to-substrate ratio (w/w). Each sample
was desalted using a Discovery DSC-18 C18 SPEcolumn (SUPELCO, Bellefonte, PA) and concentrated
to a volume of ~50 μL. The peptide concentration was
measured using the BCA assay.
SRM assay development
Seven proteotypic peptides of ERG protein were selected
and stable isotope-labeled heavy peptides with C-terminal
[13C6
15N2] lysine or [
13C6
15N4] arginine were synthesized
(ThermoFisher Scientific, Waltham, MA) for SRM assay
development [33]. SRM parameters were optimized by dir-
ect infusion experiments on a TSQ Quantum Ultra triple
quadrupole mass spectrometer (ThermoFisher Scientific),
where the 6-8 most intense fragment ions for each peptide
were selected as precursor-to-fragment transitions and the
collision energy (CE) of each transition was optimized
automatically in SRM mode. The peptides were dissolved
in a buffer containing 50% acetonitrile and 0.1% formic
acid, and the infusion rate was 300 nL/min. The transitions
and corresponding optimal CE values from the infusion
experiments were further validated for optimal detec-
tion of the target peptides in actual LC-SRM analysis. In
this step 50 fmol/μL of heavy peptide standards were
spiked with 0.5 μg/μL of VCaP-derived tryptic peptides,
and 2 μL of the sample was analyzed using a nanoAC-
QUITY UPLC® system (Waters Corporation, Milford,
MA) and a TSQ Vantage triple quadrupole mass spec-
trometer (ThermoFisher Scientific). Transitions with
lower intensity or higher level of interference were re-
moved, and the three best transitions were retained for
each peptide in developing the final SRM assays.
PRISM fractionation
Five fmol/μL of high-purity heavy peptides (purity > 97%)
were spiked with 1 μg/μL of peptides from each sample,
and the peptides were separated following the PRISM
workflow using high pH reversed-phase capillary LC on a
nanoACQUITY UPLC® system as described previously
[30,33]. Briefly, separations were performed using a capil-
lary column packed in-house (3 μm Jupiter C18 bonded
particles, 200 μm i.d. × 50 cm long) at a flow rate of
3.3 μL/min on binary pump systems, using 10 mM ammo-
nium formate (pH 10) as mobile phase A and 10 mM am-
monium formate in 90% acetonitrile (pH 10) as mobile
phase B. Forty-five microliters of each sample (1 μg/μL)
were loaded onto the column and separated using a binary
gradient of 5-15% B in 15 min, 15-25% B in 25 min, 25-
45% B in 25 min, and 45-90% B in 38 min. Following the
LC separation, the eluate from the capillary column was
split into two flowing streams (1:10 split) via a T-union.
The smaller fraction of eluate was sent at a flow rate of
300 nL/min to a TSQ Quantum Ultra triple quadrupole
mass spectrometer for on-line SRM monitoring of heavy
peptide standards. TSQ Quantum Ultra was operated with
ion spray voltages of 2400 ± 100 V, a capillary offset
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capillary inlet temperature of 220°C. Tube lens voltages
were obtained from automatic tuning and calibration
without further optimization. Both Q1 and Q3 were set at
unit resolution of 0.7 FWHM and Q2 gas pressure was 1.5
mTorr. A scan width of 0.002m/z and a dwell time of
10 ms were used. The remaining fraction of the capillary
column eluate, flowing at a rate of 3 μL/min, was automat-
ically collected every 1 min into a 96-well plate using a
Triversa NanoMate® system (Advion BioSciences, Ithaca,
NY) over the course of ~100 min LC separation. Prior to
peptide fraction collection, 17 μL of water was added to
each well in the plate to avoid peptide loss and also to di-
lute the peptide fraction for LC-SRM analysis. The frac-
tion containing a target peptide was intelligently selected
based on the retention time of the peptide obtained by on-
line monitoring. The detailed method for intelligent selec-
tion was described in our previous study [30,32].
LC-SRM analysis
Following high pH capillary reversed-phase LC (RPLC)
separation and intelligent selection, the fractions con-
taining the target peptides were subjected to conven-
tional LC-SRM analysis. All peptide fractions were
analyzed using a nanoACQUITY UPLC® system coupled
on-line to a TSQ Vantage triple quadrupole mass spec-
trometer. The UPLC® system was equipped with a
nanoACQUITY UPLC BEH 1.7 μm C18 column (100 μm
i.d. × 10 cm), which was connected to a chemically
etched 20 μm i.d. fused-silica emitter via a stainless steel
union. Four microliters of each peptide fraction were
loaded onto the column at a flow rate of 1 μL/min for
5 min. Peptides were separated at a flow rate of 500 nL/
min, using a 10-min gradient from 10-35% acetonitrile
in water. The TSQ Vantage was operated in the same
manner as the TSQ Quantum Ultra. The raw data ac-
quired on the TSQ Vantage triple quadrupole MS were
imported into Skyline software [34] for visualization of
chromatograms of target peptides and to quantify the
detected peptides. The most abundant transition for
each peptide was used for quantification unless interfer-
ence was observed. Peak detection and integration were
based on two criteria: 1) the same retention time; and 2)
approximately the same relative peak intensity ratios
across multiple transitions between light peptide and
heavy peptide standards. All data were manually inspected
to ensure correct peak detection and accurate integration.
Light to heavy peak area ratios were used to quantify
target peptides.
ELISA assay
An ELISA was developed for use in detection of ERG
protein in biospecimens, including body fluids such as
sera and urine. Purified recombinant ERG protein wasused as a source of antigen for development. Different
combinations of antibodies were used as capture and de-
tection reagents in an antigen capture assay, or sandwich
ELISA, to select for optimal reactivity. ELISA procedures
using cell lysates were carried out in NUNC 96-well flat
bottom Maxisorp plates (Thermo Scientific, Rockford,
IL). Plates were coated with 1 μg/mL of ERG MAb 9FY,
using 100 μL coating buffer (50 mM NaHCO3, pH 9.6).
The reactions were carried out in duplicate. The plates
were covered with microplate sealers (Thermo Scientific)
and incubated at 4°C overnight. The next day, plates
were washed 4 times with wash buffer (1X PBS +
Tween-20; KD Medical, Columbia, MD) and blocked
with 200 μL blocking buffer (StartingBlock; Thermo
Scientific), covered, and incubated for 1 h at room
temperature (RT). Each set of cell samples were lysed
through 5 freeze-thaw cycles in a dry ice/methanol bath,
followed by sonication at 35% amplitude with 15 s pulses
for 10 min. Following pre-clearing by centrifugation
(13,000 × g for 10 min), lysates (100 μL) were loaded
onto plates after washing once post-blocking, covered,
and incubated for 1 h at 37°C. Plates were washed 4
times with wash buffer, and incubated with 100 μL bio-
tinylated ERG antibody (2 μg/mL; Origene), covered for
1 h at 37°C. Plates were again washed 4 times with wash
buffer and then incubated with 100 μL of Streptavidin-
HRP conjugated antibody diluted as per manufacturer’s
protocols (KPL Inc., Gaithersburg, MD), covered for 1 h
at 37°C. Plates were washed 4 times with wash buffer,
100 μL of K-Blue Aqueous TMB substrate (Neogen,
Lexington, KY) was added to the plates, and incubated
uncovered for 30 min at RT. Sulfuric acid (2 N, 100 μL)
was added to the plates post-incubation to stop the reac-
tions. Plates were immediately read at 450 nm to meas-
ure absorbance. All dilutions of reagents were performed
in ELISA diluent (20% NGS in 1X PBS with 0.1%
Triton-X 100).
Western blot
VCaP, LNCaP, and HEK293 cells were trypsinized and
washed twice with PBS. VCaP cells were counted on a
Coulter cell counter and aliquoted in appropriate quan-
tities. Cells were pelleted by centrifugation and pellets
were lysed in Mammalian Protein Extraction Reagent
(M-PER; Thermo Scientific). Following pre-clearing by
centrifugation (13,000 × g for 10 min), protein concen-
trations of cell lysates were determined by using Protein
Assay Reagent (Bio-Rad, Hercules, CA). LNCaP and
HEK293 cell lysates were spiked with purified recombin-
ant ERG protein at the indicated concentrations, and
then both sets of lysates were separated on NuPAGE
Bis-Tris (4-12%) gels (Life Technologies) and transferred
onto PVDF membranes. Membranes were blocked in
Blocking Buffer (LI-COR, Lincoln, NE) and incubated
Table 1 Detection of recombinant ERG3 protein spiked
into LNCaP cells using PRISM-SRM
ERG peptide Data point (on-column protein amount)
6.7 pg 20 pg 67 pg 400 pg
VIVPADPTLWSTDHVR ND √ √ √
HMPPPNMTTNER ND ND √ √
ITTRPDLPYEPPR ND ND √ √
√ indicates that the peptide was detected.
ND indicates that the peptide was not detected.
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Biocare Medical Inc., Concord, CA), and GAPDH (Santa
Cruz biotechnology, Santa Cruz, CA). Membranes were
washed in Tris-Buffered Saline + Tween 20 (TBST) before
incubation with appropriate secondary antibodies (goat
anti-Mouse IRDye 800CW or goat anti-Rabbit IRDye
680CW, LI-COR). Signals of proteins detected were visu-
alized and quantitatively measured using the Odyssey
infra-red imaging scanner and software (LI-COR).
Quantitative RT-PCR
RNA was isolated from cell pellets using RNeasy RNA Iso-
lation Kit (Qiagen, Germantown, MD). The total amount
of RNA isolated was used for reverse transcription (RT)
for a final volume of 20 μL of cDNA, and real-time qRT-
PCR (TaqMan) was performed using 5 μL of the cDNA.
TaqMan primers and probe for quantitative evaluation of
ERG3 were as follows: forward: 5′-CAGGTCCTTCTT
GCCTCCC-3′; reverse: 5′-TATGGAGGCTCCAATTGA
AACC-3′; probe: 5′-FAM-TGTCTTTTATTTCTAGCC
CCTTTTGGAACAGGA-TAMRA-3′. The expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as an endogenous control gene in each reaction
(Applied Biosystems, Grand Island, NY). RNA samples
without reverse transcription were included as negative
controls in each assay. Results are represented by the aver-
age Ct values from individual runs.
NanoString platform RNA isolation and assessment
Pellets from VCaP-spiked female urine and VCaP-spiked
LNCaP cell mixture were resuspended in 100 μL of
extraction buffer. RNA was isolated using a PicoPure
RNA isolation kit (Life Technologies), according to man-
ufacturer’s protocols. RNA quality was measured using a
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA) and a
NanoDrop ND-100 spectrophotometer (Thermo Scientific).
NanoString nCounter analysis
RNA isolated from each sample was input for NanoString
nCounter analysis (NanoString Technologies, Seattle, WA).
Hybridization and NanoString nCounter were processed
according to manufacturer’s protocols reported previously
[35,36]. In brief, hybridizations were carried at 65°C for
20 h, after which the hybridization products were applied
to the nCounter Preparation Station for automated removal
of excess probe and immobilization of probe-transcript
complexes on a streptavidin-coated cartridge. Data were
collected using the nCounter Digital Analyzer by count-
ing the individual barcodes. Data were analyzed using
the nCounter™ digital analyzer software (Version 2.1.1).
The raw data were normalized through the following
two steps: 1) The geometric mean of spiked-in exogen-
ous positive controls was used to correct for differences
resulting from assay efficiency (hybridization, purification,binding, etc.); 2) Spiked-in negative controls were used
to remove hybridization background. All signals below
mean background +2 standard deviations (SD) were
considered as hybridization background and subtracted
from the raw data.
Results
PRISM-SRM detection of recombinant ERG protein spiked
into LNCaP cells
To define ERG detection sensitivity in cells, purified re-
combinant ERG3 protein (30, 100, 300, 1000, 6000 pg) was
spiked into 1,000,000 TMPRSS2-ERG negative LNCaP cells
and analyzed by PRISM-SRM. After cell lysis, tryptic diges-
tion and sample clean-up, 1/15 of each sample was used
for PRISM-SRM analysis. Three ERG peptides were con-
sistently detected, with peptide VIVPADPTLWSTDHVR
(residues 125-160 in the predicted amino acid sequence of
ERG3) displaying the best response (Table 1). Using this
peptide, ERG3 protein could be detected at levels as low
as 20 pg (Table 1 and Figure 1A). The response curve
showed excellent linearity in the detected spiking range:
300-6,000 pg ERG3 protein spiked into 1,000,000 LNCaP
cells (Figure 1B).
PRISM-SRM detection of ERG protein in the VCaP-LNCaP
mixed cells
TMPRSS2-ERG positive VCaP cells (0, 10, 100, 1,000,
10,000, and 100,000) were incrementally spiked into
1,000,000 LNCaP cells to simulate prostate tumor tissue
samples, which contain mixtures of tumor and non-
malignant stroma, and 1/10 of each sample was analyzed
using PRISM-SRM. In these samples two ERG peptides,
VIVPADPTLWSTDHVR (amino acid positions 125-140)
and HMPPPNMTTNER (amino acid positions 112-123),
were confidently detected from samples corresponding
to 10,000 VCaP cells (Table 2). Extracted ion chromato-
grams (XICs) of the two peptides are shown in Figure 2.
PRISM-SRM detection of ERG protein in the VCaP-urine
system
VCaP cells (0, 1,000, 5,000, 10,000, 20,000, 50,000, 100,000,
and 1,000,000) were spiked into 5 mL of human female
urine to simulate prostate cancer urine sediment samples,
and analyzed using PRISM-SRM. Due to the limited total
Figure 1 Detection of ERG peptide VIVPADPTLWSTDHVR from LNCaP cells. Different amounts of recombinant ERG3 protein (6.7 pg, 20 pg,
67 pg, 400 pg) was spiked into LNCaP cells. A. XICs of peptide VIVPADPTLWSTDHVR from the different data points. Heavy indicate heavy internal
standard peptide; Light indicate endogenous peptide. N.D.: not detected. B. Response curve.
Table 2 Detection of ERG protein in VCaP cells spiked
into LNCaP cells using PRISM-SRM
ERG peptide Data point (number of VCaP cells)
1 10 100 1000 10000
VIVPADPTLWSTDHVR ND ND ND ND √
HMPPPNMTTNER ND ND ND ND √
√ indicates that the peptide was detected.
ND indicates that the peptide was not detected.
He et al. Journal of Translational Medicine  (2015) 13:54 Page 6 of 14protein content (i.e., the low yield of urinary proteins from
urine samples) in these samples, 60% of each sample (as
opposed to 1/10) was used for the analysis, except for the
highest concentration data point sample (where 1/6 of the
sample was used for the analysis). The results showed that
four ERG peptides were detected and peptide VIV-
PADPTLWSTDHVR had the best response, which is con-
sistent with the above observations (Table 3). XICs of
VIVPADPTLWSTDHVR showed that this peptide could
Figure 2 Detection of ERG protein in the VCaP-LNCaP system. XICs of the two ERG peptides detected from ~ 10,000 VCaP cells. Heavy
indicates heavy internal standard peptide; Light indicates endogenous peptide.
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(Figure 3A). Based on the peak area ratio of this ERG pep-
tide and the concentration of heavy peptide standard, the
abundance of ERG protein was estimated as ~18,000 cop-
ies per VCaP cell, i.e., 1.8 fg per cell. The response curve of
the best detected peptide, VIVPADPTLWSTDHVR, again
showed good linearity (Figure 3B).
Detection of ERG protein by ELISA
For the development of an in-house ELISA for ERG pro-
tein detection, we initially tested the affinity of several anti-
bodies available against ERG protein. The reactivity data
indicated that the ERG MAb 9FY antibody showed high af-
finity when compared to antibodies from Epitomics, Ori-
gene, and Santa Cruz (Figure 4A). As the sandwich ELISA
format requires two antibodies that recognize the ERGTable 3 Detection of ERG protein in VCaP cells spiked into hu
ERG peptide Data point (number of VCaP cells)
0 600 3000
VIVPADPTLWSTDHVR ND √ √
HMPPPNMTTNER ND ND ND
MVGSPDTVGMNYGSYMEEK ND ND ND
ITTRPDLPYEPPR ND ND ND
√ indicates that the peptide was detected.
ND indicates that the peptide was not detected.protein at non-overlapping sites, we used recombinant
ERG protein to test a series of antibody combinations for
the capture and detection of ERG. Our results showed that
a combination of ERG MAb 9FY for capture and Origene
ERG biotinylated antibody (Clone 5 F12) has high sensitiv-
ity for detecting ERG protein (Figure 4B). We utilized this
specific antibody combination for generating a standard
curve for the detection of ERG protein (Figure 4C), as well
as defining the limit of detection for ERG, which was found
to be 30 pg. The results showed a linear relationship with
respect to the concentration of ERG protein and absorb-
ance values noted. A similar linear relationship was ob-
served with recombinant ERG spiked into cell lysates.
However, cell lysates from the VCaP-LNCaP mixed cell
population did not yield quantifiable ERG data using
ELISA methods, presumably due to an overabundance ofman female urine
6000 12000 30000 60000 170000
√ √ √ √ √
√ √ √ √ √
ND ND ND √ √
ND ND ND ND √
Figure 3 Detection of ERG peptide VIVPADPTLWSTDHVR in the VCaP-urine system. A. The number of VCaP cells for each PRISM-SRM
analysis data point was 600, 3,000, 6,000, 12,000, 30,000, 60,000, 170,000, respectively. Heavy indicates heavy internal standard peptide; Light
indicates endogenous peptide. B. The light/heavy peak area ratio shows good linearity.
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the sandwich ELISA to evaluate detection limit of ERG
protein in VCaP cells directly (without mixing with LNCaP
cells). The number of VCaP cells considered for analysis
included: 1,000, 5,000, 10,000, 15,000, 20,000, 30,000,
40,000, 50,000, 75,000 and 100,000. The results indicated
that the limit of detection was 10,000 cells (Figure 4D).
Based on the ERG protein quantification results derived
from the 20,000-cell data point, the absolute concentration
of ERG approximates 9 fg per cell.Detection of ERG protein by western blot
To assess the detection limit of ERG protein by western
blot, we used the HEK293 cell line, which lacks expres-
sion of TMPRSS2-ERG. Recombinant ERG protein was
added to 15 μg equivalent of HEK293 cell lysate in the
following amounts: 100, 50, 25, 12.5, 6.25, 3.125, 1.562,
0.781, 0.390 and 0.195 ng. As expected, a band corre-
sponding to 55 kDa was noted in all the cell lysates
spiked with recombinant ERG protein except for the
control (Figure 5A). The intensity of the signal was
Figure 4 Detection of ERG protein using ELISA. A. Evaluation of ERG antibody reactivity in the ELISA format. B. Capture and detection
antibody combinations for development of antigen capture assay (sandwich ELISA). C. The limit of detection of purified recombinant ERG protein
was 30 pg. D. The limit of detection of ERG protein from VCaP cell lysates (without mixing with LNCaP cells) was 10,000 cells.
Figure 5 Western blot analysis for detection of ERG protein in cell lysates. A. A 55 kDA band corresponding to ERG protein was observed
in HEK293 cell lysates spiked with purified recombinant protein in all lanes except the HEK293 only sample. GAPDH was used as a loading
control. B. The limit of detection was 0.195 ng of ERG protein in western blot analysis. C. Cell mixtures containing VCaP and LNCaP cells, kept
constant with 100,000 total cells, revealed that 10,000 VCaP cells are detected by western blot. GAPDH was again used as a loading control.
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COR). The four highest dilutions were presented as scat-
ter plot in Figure 5B. This showed that the limit of
detection was 195 pg of the recombinant ERG protein.
We then quantified endogenous ERG protein present in
VCaP cells (10,000 to 100,000) mixed with ERG negative
LNCaP cells (the overall cell number was kept constant
at 100,000). The results showed that ERG protein signal
was detected in as little as 10,000 VCaP cells (Figure 5C).
The analysis of the signals through scanning densitom-
etry revealed that the signal from 10,000 VCaP cells cor-
responds approximately to 440 pg of ERG based on the
standard curve.
Detection of ERG3 mRNA by qRT-PCR
In an effort to evaluate the detection limit of ERG at the
mRNA level with respect to cell number, we utilized
TMPRSS2-ERG fusion harboring VCaP cells. The VCaP-
LNCaP mixed cell population was not amenable for the
assay due to high RNA concentrations in a relatively
small sample size, thus we utilized urine samples incre-
mentally spiked with VCaP cells. ERG3, the longest func-
tional splice form of ERG, was consistently detected
from cDNA corresponding to as few as 100 VCaP cells.
The Ct values of the internal control, GAPDH, corre-
sponded with ERG values, and both became progres-
sively lower as cell numbers increased (Figure 6).
Detection of ERG3 by NanoString
RNA extracted from the LNCaP-VCaP mixed cell sam-
ple showed high quality RNA with the median RNA in-
tegrity number (RIN) of 8.7 (range 8.3-9.0) and 260/280
of 1.84 (range 1.84-2.03), respectively. However, VCaPFigure 6 Real time quantitative RT-PCR evaluation of ERG in VCaP cel
detectable in as few as 100 cells.cells spiked urine samples failed measurement by both
the Bioanalyzer (Nanochip) and Nanodrop, showing an
undetectable RIN or 260/280 (Table 4). However, all of
the RNA isolated from each sample was used for
hybridization, therefore, analysis of ERG was not affected
by RNA assessment and the NanoString readout directly
correlated with the initial number of cells in each sam-
ple. Figure 7 shows that the NanoString detected the
highest level of ERG (copy number) in urine spiked with
one million VCaP cells (~11,000 copies, lower panel).
Around 1,000 copies of ERG were detected in both
LNCaP cells and urine samples spiked with 100,000
VCaP cells, while 81 and 57 copies of ERG were detected
in LNCaP cells and urine spiked with 10,000 VCaP cells,
respectively (Table 5). Given that the number of RNA
copies detected was decreased by almost the identical
fold change of VCaP cell numbers, ERG should be de-
tected for both LNCaP cells and urine spiked with 1,000
VCaP cells by the NanoString nCounter system, with
around 5 copies each. The lack of ERG detection from
both of these cell preparations might result from our
stringent background subtraction in which we removed
all signals below mean background + 2 standard devia-
tions (median of SD = 5). Extrapolating from the above
results, we should be able to detect around 25 copies of
RNA in 5000 VCaP cells (1/2 fold of the number from
10, 000 VCaP cells), by the NanoString from both spiked
LNCaP cells and urine.
Discussion
The discovery of fusion transcripts involving ERG coding
sequences and TMPRSS2 promoter sequences has eluci-
dated a role for ERG in the initiation and progression ofls spiked into female urine. mRNA transcripts of ERG3 were
Table 4 RNA assessment by Bioanalyzer and Nanodrop
Sample Bioanalyzer Nanodrop
ng/mL RIN Total RNA (ng) ng/mL 260/280 Total RNA (ng)
106 LNCaP 100 8.3 2800 110 1.93 3080
106 LNCaP + 101 VCaP 540 8.6 15120 513 1.96 14364
106 LNCaP + 102 VCaP 280 8.9 7840 302 1.91 8456
106 LNCaP + 103 VCaP 350 9 9800 393 1.84 11004
106 LNCaP + 104 VCaP 350 8.6 9800 333 2.03 9324
106 LNCaP + 105 VCaP 250 8.8 7000 277 1.9 7756
5 mL Urine 30 ND 840 11 ND 308
5 mL Urine + 102 VCaP 30 ND 840 6 ND 168
5 mL Urine + 103 VCaP 10 ND 280 8 ND 224
5 mL Urine + 104 VCaP 80 ND 2240 9 ND 252
5 mL Urine + 105 VCaP 10 ND 280 22 ND 616
5 mL Urine + 106 VCaP 130 ND 3640 83 ND 2324
ND indicates that a reading was not detected.
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has been used as a diagnostic test for prostate cancer
since the 1990s. Although this is a convenient assay
using blood samples, the specificity of the assay is only
around 20% [15,16]. This has led to frequent overtreat-
ment and its related consequences. This scenario has
also spurred significant interest in the search for new
and highly specific biomarkers for the detection of pros-
tate cancer. In this regard, tests involving various forms
of PSA have also been utilized with moderate success.
The detection of ERG protein expression in biopsied tis-
sues from prostate cancer patients using the highly specific
ERG MAb 9FY has been valuable for the stratification ofFigure 7 Detection of ERG using NanoString. ERG copy number was de
cells spiked into 5 mL of female urine.prostate cancer. Several laboratories, including ours, have
shown that ERG expression is detected only in prostate
tumor tissue and not in matched controls, consistent with
studies showing low/undetectable levels of expression of
endogenous ERG protein in prostate epithelial cells [18,19].
It has also been demonstrated that PRISM-SRM detects
ERG protein only in the TMPRSS2-ERG fusion positive tu-
mors, and not in the TMPRSS2-ERG fusion negative tu-
mors [33]. Recently, we have completed a study involving
1000 prostate whole mount specimens and the results con-
firmed our earlier observations ([20]; unpublished data).
In addition, there is a striking population difference as
Caucasian Americans registered ERG expression in abouttected from 10,000 VCaP cells spiked into LNCaP cells, as well as VCaP
Table 5 Detection of ERG in VCaP cells spiked into LNCaP
cells and human female urine using NanoString nCounter
Spiked
Sample
Number of VCaP Cells
0 101 102 103 104 105 106
106 LNCaP ND ND ND ND 81.85 1033.8 ND
5 mL Urine ND ND ND ND 57.55 1004.12 10945.38
ND indicates that a reading was not detected.
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sion in African Americans (25%) [20,23].
The analysis of biopsied tissues is currently carried out
by IHC which is labor intensive and, for the most part,
qualitative rather than quantitative in nature. Quantita-
tive approaches, based on either a single or a combin-
ation of biomarkers, are therefore desirable for the
diagnosis and prognosis of prostate cancer. Considering
this, we sought to develop assays for assessing the level
of ERG oncoprotein in cells from multiple sample types
including tissue and urine sediment. Such assays are
likely to be useful in clinical applications such as patient
stratification. For example, it is well known that prostate
cancer cells are present in urine/post-DRE urine samples
of patients, due to manual manipulation of the prostate,
which represent a truly non-invasive source for analysis
[37]. In comparison to analysis involving tissues contain-
ing endothelial cells in addition to prostate tumor cells
as a source of analysis, the cells present in the post-DRE
urine may be mostly devoid of endothelial cells. In such
a scenario, the observed ERG signal could be attributed
to its expression from tumor cells. Recently, the FDA
approved the PCA3 urine test based on RNA evaluation,
which is used in the context of making decisions about
repeat biopsies [38]. Along the same line, cells in urine
samples could be tested for the presence of ERG
oncoprotein.
Several different technologies were evaluated for quan-
tification of ERG protein with the goal of identifying
their detection limit. Commercially available purified
recombinant ERG protein, established prostate cancer
cell lines VCaP (TMPRSS2-ERG fusion positive) and
LNCaP (TMPRSS2-ERG fusion negative), and female
urine were used to prepare three types of samples mim-
icking cell lines, tissues, and urine sediments for the
analysis. It is worth noting that the antibody-free, MS-
based PRISM-SRM assay enables the detection of 20 pg
of recombinant ERG protein spiked into LNCaP cell
lysate. In a mixed cell population model containing a
constant number (1,000,000) of LNCaP cells with an
incremental number of VCaP cells, the assay was able to
detect and quantify ERG protein in 10,000 VCaP cells.
Interestingly, the same assay detected ERG protein in as
few as 600 VCaP cells spiked into female urine samples.
This sensitivity difference between the mixed cell linesamples and the female urine is most likely because the
spiked urine sample has less total protein content than
the mixed VCaP/LNCaP cell line sample, hence, when
the same amount of peptides from these two different
sample types were injected for PRISM-SRM analysis, the
effective loading of ERG is increased, and the back-
ground (i.e., matrix effects) is reduced in the simulated
urine sediment samples.
In addition to developing antibody-free assays for the
quantification of ERG protein, we have also compared
the sensitivity of both protein and RNA detection
methods. The detection limit of the former assay, using
ERG MAb 9FY as the capture antibody in ELISA, was in
the range of 30 pg of recombinant ERG. It should be
noted that the 9FY antibody recognizes an epitope at the
amino terminus of the ERG protein and has the poten-
tial to detect protein encoded by all TMPRSS2-ERG vari-
ants. The limit of detection for western blot analysis was
approximately 195 pg of recombinant ERG protein.
Thus, PRISM-SRM at a 20 pg detection limit was the
most sensitive of the three methods. With regard to the
detection of cells expressing ERG, both ELISA and west-
ern blot methods exhibited the sensitivity of detecting
10,000 VCaP cells, the same as the PRISM-SRM assay.
The comparison studies were also expanded to include
methods detecting mRNA by qRT-PCR and NanoString.
Quantitative RT-PCR showed high sensitivity as it was
able to detect RNA from a minimum of 100 VCaP cells
spiked in female urine. It should be pointed out that our
RNA detection method utilized total RNA without in-
volving a pre-amplification step in the analysis. While
the NanoString has the advantage of analyzing the ex-
pression of multiple genes simultaneously, it was found
to be less sensitive than qRT-PCR assay, as it detected
RNA from 10,000 VCaP cells spiked into LNCaP cells.
Several factors may contribute to the differences in sen-
sitivity with respect to detection limit in the analysis of
the mixed VCaP/LNCaP cells and VCaP spiked urine
samples. These include: i) dilution of ERG protein in a
mixed cell population model; ii) the lysis of cells involv-
ing freeze-thaw and sonication methods; iii) differences
in the stability and half-life of the analytes; and iv) limi-
tation of the sensitivity of capturing and detection anti-
bodies in ELISA.
Conclusions
In summary, the data presented here suggest that qRT-
PCR and PRISM-SRM platforms are highly sensitive in
detecting TMPRSS2-ERG transcripts and proteins, re-
spectively. Compared to other RNA and protein detec-
tion technologies, the PRISM-SRM assay has several
significant advantages: it is not affected by RNA stability,
it does not rely on a specific antibody, and it is ideal
for isoform-specific detection with high multiplexing
He et al. Journal of Translational Medicine  (2015) 13:54 Page 13 of 14capability (e.g., multiplexed quantitative analysis of ERG3
and ERG8 isoforms; data not shown). Therefore, PRISM-
SRM assays can be adapted to detect ERG protein in
cells present in clinical specimens (e.g., tissue, post-DRE
urine, and circulating tumor cells in blood), and cell-
free ERG protein present in the blood sera, providing an
opportunity for its use in the clinical setting for detec-
tion in prostate cancer patients, and define treatment
strategies in accordance.
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